134 related articles for article (PubMed ID: 28535103)
1. Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology.
Shah-Manek B; Galanto JS; Nguyen H; Ignoffo R
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S13-S20. PubMed ID: 28535103
[TBL] [Abstract][Full Text] [Related]
2. Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.
Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S34-S48. PubMed ID: 28535104
[TBL] [Abstract][Full Text] [Related]
3. Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.
Frois C; Howe A; Jarvis J; Grice K; Wong K; Zacker C; Sasane R
J Manag Care Spec Pharm; 2019 Feb; 25(2):246-259. PubMed ID: 30698093
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of the Effect of Cancer Treatment on Work Productivity of Patients and Caregivers.
Kamal KM; Covvey JR; Dashputre A; Ghosh S; Shah S; Bhosle M; Zacker C
J Manag Care Spec Pharm; 2017 Feb; 23(2):136-162. PubMed ID: 28125370
[TBL] [Abstract][Full Text] [Related]
5. The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China.
Bao Y; Liu Y; Ma R; Zhang P; Li X
J Glob Health; 2023 Nov; 13():04140. PubMed ID: 37934965
[TBL] [Abstract][Full Text] [Related]
6. NCCN Evidence Blocks.
Carlson RW; Jonasch E
J Natl Compr Canc Netw; 2016 May; 14(5 Suppl):616-9. PubMed ID: 27226499
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Additional Benefit Assessment Methods for Time-to-Event Endpoints Using Hazard Ratio Point Estimates or Confidence Interval Limits by Means of a Simulation Study.
Büsch CA; Kirchner M; Behnisch R; Kieser M
Med Decis Making; 2024 May; 44(4):365-379. PubMed ID: 38721872
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS.
Yoon NR; Na YJ; Lee JH; Song I; Lee EK; Park MH
J Cancer Res Clin Oncol; 2024 Mar; 150(3):113. PubMed ID: 38436796
[TBL] [Abstract][Full Text] [Related]
9. The evolution of payer management of oncology drugs in the United States between 2017 and 2022.
Runyan A; Yi J; Honcz J
J Manag Care Spec Pharm; 2023 Oct; 29(10):1138-1149. PubMed ID: 37695273
[No Abstract] [Full Text] [Related]
10. The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing-Challenging the "more is better" dogma.
Maués J; Loeser A; Cowden J; Johnson S; Carlson M; Lee S
Clin Trials; 2024 Jun; 21(3):358-362. PubMed ID: 38385314
[TBL] [Abstract][Full Text] [Related]
11. Improving Quality and Cost of the Oncology Advanced Practice Provider Chemotherapy Privileging Process.
Cherian LI; Madsen LT; Bazzell AF
Clin J Oncol Nurs; 2024 May; 28(3):263-271. PubMed ID: 38830244
[TBL] [Abstract][Full Text] [Related]
12. Evaluating Frameworks That Provide Value Measures for Health Care Interventions.
Mandelblatt JS; Ramsey SD; Lieu TA; Phelps CE
Value Health; 2017 Feb; 20(2):185-192. PubMed ID: 28237193
[TBL] [Abstract][Full Text] [Related]
13. Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshop.
Latimer NR; Pollard D; Towse A; Henshall C; Sansom L; Ward RL; Bruce A; Deakin C
BMC Health Serv Res; 2021 May; 21(1):412. PubMed ID: 33941174
[TBL] [Abstract][Full Text] [Related]
14. [Health-economic aspects of radiotherapy].
Vandemaele M; Lievens Y
Rev Med Liege; 2024 May; 79(S1):117-122. PubMed ID: 38778659
[TBL] [Abstract][Full Text] [Related]
15. Drug Shortages in Oncology: ASCO Clinical Guidance for Alternative Treatments.
Santos ES; Oliver TK; Lacchetti C; Geisel R; Wilfong LS; Fader AN; Eng C
JCO Oncol Pract; 2024 Jan; 20(1):19-32. PubMed ID: 37963306
[TBL] [Abstract][Full Text] [Related]
16. Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement.
Cui W; Rocconi RP; Thota R; Anderson RA; Bruinooge SS; Comstock IA; Denduluri N; Gassman A; Gralow J; Hutt KJ; Amiri-Kordestani L; Lambertini M; Leighton J; Lu KH; Mostoufi-Moab S; Pollastro T; Pradhan S; Saber H; Schenkel C; Spratt D; Wedam S; Phillips KA
Lancet Oncol; 2023 Oct; 24(10):e415-e423. PubMed ID: 37797647
[TBL] [Abstract][Full Text] [Related]
17. Association between oral targeted cancer drug net health benefit, uptake, and spending.
Lau-Min KS; Wu Y; Rochester S; Bekelman JE; Kanter GP; Getz KD
J Natl Cancer Inst; 2024 May; ():. PubMed ID: 38745430
[TBL] [Abstract][Full Text] [Related]
18. Common Sense Oncology: Equity, Value, and Outcomes That Matter.
Wilson BE; Sengar M; Tregear M; van der Graaf WTA; Luca Battisti NM; Csaba DL; Soto-Perez-de-Celis E; Gyawali B; Booth CM
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e100039. PubMed ID: 38788178
[TBL] [Abstract][Full Text] [Related]
19. Academia and society should join forces to make anti-cancer treatments more affordable.
Berns A
Mol Oncol; 2024 Jun; 18(6):1351-1354. PubMed ID: 38634213
[TBL] [Abstract][Full Text] [Related]
20. Rethinking clinical oncology drug research in an era of value-based cancer care: A role for chemotherapy pathways.
Hoverman JR
Cancer Med; 2020 Aug; 9(15):5306-5311. PubMed ID: 32524722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
